Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.21

0.55 (1.01%)

, GILD

Gilead

$77.24

-0.79 (-1.01%)

19:54
10/04/16
10/04
19:54
10/04/16
19:54

FDA mandates boxed warning on some hepatitis drugs after virus reactivation

The FDA issued a warning Tuesday about the risk of hepatitis B becoming an active infection again in "any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death." The agency is requiring a boxed warning, its most prominent alert, be added to the drug labels of the medications in question that directs health professionals to screen and monitor for HBV in all patients receiving DAA treatment. It is currently unknown why the reactivation occurs, the agency said. The FDA noted that "we identified 24 cases of HBV reactivation reported to FDA and from the published literature in HCV/HBV co-infected patients treated with DAAs during the 31 months from November 22, 2013 to July 18, 2016. This number includes only cases submitted to FDA, so there are likely additional cases about which we are unaware. Of the cases reported, two patients died and one required a liver transplant. HBV reactivation was not reported as an adverse event in the clinical trials submitted for the DAA approvals because patients with HBV co-infection were excluded from the trials." The FDA announcement included a list of direct-acting antivirals, which named Bristol-Myers' (BMY) Daklinza; Gilead's (GILD) Epclusa, Harvoni and Sovaldi; Johnson & Johnson's (JNJ) Olysio; AbbVie's (ABBV) Technivie and Viekira Pak; and Merck's (MRK) Zepatier. Reference Link

BMY

Bristol-Myers

$55.21

0.55 (1.01%)

GILD

Gilead

$77.24

-0.79 (-1.01%)

JNJ

Johnson & Johnson

$118.82

0.01 (0.01%)

ABBV

AbbVie

$63.00

-0.23 (-0.36%)

MRK

Merck

$62.46

-0.06 (-0.10%)

  • 04

    Oct

  • 04

    Oct

  • 07

    Oct

  • 09

    Oct

  • 18

    Oct

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 11

    Nov

BMY Bristol-Myers
$55.21

0.55 (1.01%)

09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
GILD Gilead
$77.24

-0.79 (-1.01%)

10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
JNJ Johnson & Johnson
$118.82

0.01 (0.01%)

08/18/16
UBSW
08/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson remains a top large cap pick, says UBS
UBS analyst Matt Miksic said Johnson & Johnson remains a top large cap diversified pick for the year. The analyst said yesterday's court ruling that invalidated the company's Remicade patent was expected and could delay the Q4 biosimilar launch but its robust pharma pipeline remains under-appreciated and should make up the difference. He said he continues to see further clarity regarding potential U.S. biosimilar competition for Remicade as positive for the stock. Miksic reiterated his Buy rating and $137 price target on Johnson & Johnson shares.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
ABBV AbbVie
$63.00

-0.23 (-0.36%)

09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
MRK Merck
$62.46

-0.06 (-0.10%)

08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.

TODAY'S FREE FLY STORIES

ATVI

Activision Blizzard

$45.08

-0.15 (-0.33%)

10:41
02/24/17
02/24
10:41
02/24/17
10:41
Options
Activision short-term calls active as shares tick higher »

Activision short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DOC

Physicians Realty Trust

$20.01

0.1 (0.50%)

10:40
02/24/17
02/24
10:40
02/24/17
10:40
Syndicate
Breaking Syndicate news story on Physicians Realty Trust »

Physicians Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

10:39
02/24/17
02/24
10:39
02/24/17
10:39
Conference/Events
CLSA technology/internet analyst holds an analyst/industry conference call »

Technology Analyst James…

RY

Royal Bank of Canada

$74.47

-0.41 (-0.55%)

10:37
02/24/17
02/24
10:37
02/24/17
10:37
Periodicals
RBC places Asia wealth business under review, Reuters reports »

Royal Bank of Canada has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

SB

Safe Bulkers

$1.38

0.009 (0.66%)

10:36
02/24/17
02/24
10:36
02/24/17
10:36
Upgrade
Safe Bulkers rating change  »

Safe Bulkers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 22

    Mar

STX

Seagate

$47.39

0.04 (0.08%)

10:36
02/24/17
02/24
10:36
02/24/17
10:36
Options
Seagate put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

10:35
02/24/17
02/24
10:35
02/24/17
10:35
General news
The 3.7% U.S. January new home sales bounce »

The 3.7% U.S. January new…

SQ

Square

$17.23

0.075 (0.44%)

, TEX

Terex

$29.53

-0.38 (-1.27%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

SQ

Square

$17.23

0.075 (0.44%)

TEX

Terex

$29.53

-0.38 (-1.27%)

AERI

Aerie Pharmaceuticals

$44.25

-0.2 (-0.45%)

CLSD

Clearside Biomedical

$6.90

-0.29 (-4.03%)

PSTB

Park Sterling Bank

$12.07

-0.03 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 07

    Mar

  • 21

    Mar

  • 21

    Mar

  • 15

    May

HPE

HP Enterprise

$22.46

-2.205 (-8.94%)

, W

Wayfair

$38.32

-0.265 (-0.69%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

HPE

HP Enterprise

$22.46

-2.205 (-8.94%)

W

Wayfair

$38.32

-0.265 (-0.69%)

RIG

Transocean

$14.06

-0.25 (-1.75%)

GT

Goodyear Tire

$35.50

-0.45 (-1.25%)

JACK

Jack in the Box

$96.70

-6.9 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$13.44

-0.25 (-1.83%)

, AMCX

AMC Networks

$59.84

2.34 (4.07%)

10:31
02/24/17
02/24
10:31
02/24/17
10:31
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

WEN

Wendy's

$13.44

-0.25 (-1.83%)

AMCX

AMC Networks

$59.84

2.34 (4.07%)

CHK

Chesapeake

$5.81

0.055 (0.96%)

INTU

Intuit

$120.70

1.27 (1.06%)

HP

Helmerich & Payne

$68.53

-0.24 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MBLY

Mobileye

$46.54

-1.6 (-3.32%)

, NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Hot Stocks
Citron closes NVIDIA short, shifts focus to Mobileye »

Andrew Left's Citron…

MBLY

Mobileye

$46.54

-1.6 (-3.32%)

NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

  • 20

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
General news
Michigan sentiment slipped to an upwardly-revised 96.3 »

Michigan sentiment…

ELNK

EarthLink

$5.85

0.04 (0.69%)

, WIN

Windstream

$7.29

0.07 (0.97%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Windstream to host special shareholder meeting »

Virtual Special…

ELNK

EarthLink

$5.85

0.04 (0.69%)

WIN

Windstream

$7.29

0.07 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Wells Fargo housing analyst holds an analyst/industry conference call »

Senior Housing Analyst…

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
UBS pharma and medical devices analysts hold an analyst/industry conference call »

Major & Specialty…

JNJ

Johnson & Johnson

$122.19

1.2901 (1.07%)

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
Johnson & Johnson hs a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

10:25
02/24/17
02/24
10:25
02/24/17
10:25
Conference/Events
CLSA financial tech analyst holds an analyst/industry conference call »

Financial Technology…

CLVS

Clovis

$57.71

-3.48 (-5.69%)

10:22
02/24/17
02/24
10:22
02/24/17
10:22
Hot Stocks
Clovis reports allegations of misconduct, which it calls 'unfounded' »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$5.85

0.095 (1.65%)

10:21
02/24/17
02/24
10:21
02/24/17
10:21
Options
Renewed interest in Chesapeake Apr 7 calls »

Renewed interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

10:20
02/24/17
02/24
10:20
02/24/17
10:20
General news
Treasury Action: yields rebounded slightly »

Treasury Action: yields…

WIN

Windstream

$7.29

0.07 (0.97%)

, ELNK

EarthLink

$5.85

0.04 (0.69%)

10:20
02/24/17
02/24
10:20
02/24/17
10:20
Conference/Events
EarthLink to host special shareholder meeting »

Special Shareholder…

WIN

Windstream

$7.29

0.07 (0.97%)

ELNK

EarthLink

$5.85

0.04 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 24

    Feb

  • 01

    Mar

  • 06

    Mar

MBLY

Mobileye

$46.81

-1.335 (-2.77%)

10:19
02/24/17
02/24
10:19
02/24/17
10:19
Hot Stocks
Breaking Hot Stocks news story on Mobileye »

Citron sees Mobileye…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

$NSD

NASDAQ Market Internals

10:17
02/24/17
02/24
10:17
02/24/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$23.48

-0.27 (-1.14%)

10:16
02/24/17
02/24
10:16
02/24/17
10:16
Options
Micron put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 09

    Mar

  • 20

    Mar

  • 23

    Mar

$NYE

NYSE Market Internals

10:16
02/24/17
02/24
10:16
02/24/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.